 |
|
The Heart Profiler™ is a free comprehensive tool that presents key evidence-based clinical research from the point-of-care, physician perspective.
 |
|
|
Next Generation Search Technology
In addition to standard searching by keyword, author and journal title, our next generation technology allows you to search based on the clinical presentation of a patient using our clinical profile criteria or "Virtual Case Model" (VCM).
VCM searches allow you to describe search parameters in terms of age, New York Heart Association functional class, a variety of test results, and other descriptive parameters to find relevant published literature that match the VCM. Results will also reflect each study’s inclusion criteria, ensuring that only studies scientifically relevant to the VCM are presented.
|
More Informed Study Report Selection
The "Graph Results by Treatment Report" first sorts your search results by treatment category.
Each treatment category will separate studies that compared treatments "head to head," from studies that reviewed single treatments
For all other studies where the inclusion criteria was matched, you’ll be able to weigh the credibility of each study based on study design:
- Randomized or non-Randomized
- Multi-center or Single-center
- Meta-analysis or Non-meta-analysis
|
Unique interactive "3-D view" Study Reports
Each Study Report consists of the Title, Author(s), Publication Information, Article Summary and Data Graphs/Tables. In addition to simply reading the information, you will have an opportunity to interact with the key algorithms, data tables, etc. in each study. Change the VCM within each study to view how these key algorithms produce new results. We call this a "3-D view" of the science within a publication. Upon change, the report will recalculate the graphs and tables based on the new values for an easy yet powerful "what if" analysis.
|
| Recent Study Information |
| |
New heart failure guidelines stress early diagnosis and treatment
Early diagnosis and new treatments can help battle heart failure — a growing national problem that causes 1 million hospital admissions each year, according to new guidelines released today by the American College of Cardiology (ACC) and the American Heart Association (AHA).
Bypass may surpass stents for many heart patients
For patients with two or more diseased coronary arteries, coronary artery bypass graft (CABG) is associated with higher adjusted rates of long-term survival than stenting. The researchers found that after adjusting for factors, such as age and other illnesses, significantly more patients in the CABG group survived than those who received a stent.
Older patients can gain good relief from either medications or PCI
Patients aged 75 years or older with angina despite standard medical therapy benefit from both optimal medical therapy and percutaneous coronary intervention (PCI) to open narrowed arteries in terms of symptom relief and quality of life. The findings also suggest that these patients should be offered an invasive assessment despite their high risk of cardiac complications and previous revascularization.
Amiodarone or implanted defibrillator: which extends survival in heart failure patients?
Researchers find that a shock-only implanted defibrillator reduced the risk of death by 23% relative to placebo. Amiodarone had no beneficial effect on survival.
Carvedilol improves quality of life and increases survival
Carvedilol reduced the combined risk of death or hospitalization for a cardiovascular reason by 27% and the combined risk of death or hospitalization for heart failure by 31% as compared to those treated with placebo. Patients in the carvedilol group also spent 27% fewer days in the hospital for any reason and 40% fewer days in the hospital for heart failure than those taking the placebo.
Which is better for patients with atrial fibrillation, controlling heart rate or heart rhythm?
The researchers concluded that drug-based management of atrial fibrillation with a rhythm-control strategy offered no advantage over a rate-control strategy in cardiac or vascular deaths and may be associated with an increased noncardiovascular death rate.
Which lipid-lowering strategy is better for patients?
The study showed an advantage for patients in the intensive high-dose atorvastatin group across all subgroups studied in terms of survival, heart attacks, unstable angina requiring hospitalization, or the need for balloon angioplasty or bypass surgery compared to the standard-dose regimen with pravastatin. The researchers also concluded that after an acute coronary syndrome, the most effective target LDL cholesterol level may be lower than that recommended in current guidelines.
|
|
|
|
|
